Sequential irinotecan hydrochloride/S-1 for S-1-resistant inoperable gastric cancer: A feasibility study

Por TAKAHATA, TAKENORI, ITOH, JUGOH, SATOH, TAROH, ISHIGURO, ATSUSHI, MATSUMOTO, YOSHIFUMI, TANAKA, SATOSHI, SAITOH, SOH, TOHNO, HIROSHI, FUKUDA, SHINSAKU, SAIJO, YASUO, SAKATA, YUH
Publicado em 2012

Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer

Por Satoh, Taroh, Lee, Kyung Hee, Rha, Sun Young, Sasaki, Yasutsuna, Park, Se Hoon, Komatsu, Yoshito, Yasui, Hirofumi, Kim, Tae-You, Yamaguchi, Kensei, Fuse, Nozomu, Yamada, Yasuhide, Ura, Takashi, Kim, Si-Young, Munakata, Masaki, Saitoh, Soh, Nishio, Kazuto, Morita, Satoshi, Yamamoto, Eriko, Zhang, Qingwei, Kim, Jung-mi, Kim, Yeul Hong, Sakata, Yuh
Publicado no Gastric Cancer (2014)